
Mirxes
Founded Year
2016Stage
Series C | AliveTotal Raised
$130.1MValuation
$0000Last Raised
$87M | 1 yr agoMissing: Mirxes's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Mirxes's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Mirxes
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Mirxes is included in 4 Expert Collections, including Cancer.
Cancer
3,710 items
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Health Monitoring & Diagnostics
2,623 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
Mirxes Patents
Mirxes has filed 2 patents.
The 3 most popular patent topics include:
- Transcription factors
- Experimental cancer drugs
- Gene expression

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/17/2019 | Human cell lines, MicroRNA, Transcription factors, Molecular biology, Gene expression | Application |
Application Date | 12/17/2019 |
---|---|
Grant Date | |
Title | |
Related Topics | Human cell lines, MicroRNA, Transcription factors, Molecular biology, Gene expression |
Status | Application |
Latest Mirxes News
Feb 28, 2023
Share, Trends, Opportunity, and Forecast, 2017-2027. Segmented By Diagnosis Type (Diagnostic Imaging {Transvaginal Ultrasound, CT Scan, MRI Scan, PET Scan, Others}, Blood Test {CA-125, HER2, BRCA, KRAS Mutation, Others}, Biopsy {Image Guided Biopsy, Fine Needle Aspiration Biopsy, Others}, Others), By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others), By End User (Hospitals & Specialty Clinics, Ambulatory Care Centers, Others), By Region. February 28, 2023 12:38 ET Lyon, FRANCE New York, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Ovarian Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Diagnosis Type, By Cancer Type, By End User, By Region"" - https://www.reportlinker.com/p06424138/?utm_source=GNW Global ovarian cancer diagnostics market may register impressive growth in the forecast period, 2023-2027, due to growing demands for the early diagnosis of ovarian cancer.A surge in the instances of ovarian cancer and demands for early detection such that timely treatments could be provided is driving the growth of the global ovarian cancer diagnostics market in the upcoming five years. Ovarian cancer is one of the major factors behind rising mortality rates worldwide among the female population which is further supporting the growth of the global ovarian cancer diagnostics market in the next five years.Due to various factors like environmental factors and genetic mutations, the instances of cancer in the ovaries and cysts are increasing. Advancing healthcare services and better patient care services further substantiate the growth of the global ovarian cancer diagnostics market in the forecast years. Cancer is a chronic disease where tumors and cysts are formed in certain organs of organ sites that is abnormal and do not undergo complete cell growth before division and cause lumps at the sites.These cancer lumps hinder the functioning of the organ as well as the complete human body system thereby worsening the health of the patient. Ovarian cancer is a cancer type that takes place in the female population in their egg-producing organ, the ovaries.Diagnosis of ovarian cancer is difficult since the symptoms are very vague and are often detected only after they have already spread through the stomach and within the pelvis making it difficult to cure. Thus, better diagnostic processes and techniques are required to identify the cancer stage to treat them in due time. Growing Disease Burden Benefits Market Growth Increasing instances of ovarian cancer among the female population are the major factor that drives the growth of the global ovarian cancer diagnostics market in the upcoming five years.In the year 2020, there were 313,959 new ovarian cancer cases on a global scale. Further, the increasing mortality rate due to ovarian cancer is alarming and it further portrays the importance of the early diagnosis of ovarian cancer such that treatment could be provided. The total number of deaths caused due to ovarian cancer globally in the year 2020 was 207,252. The American Cancer Society estimates that in 2022, about 19,880 new cases of ovarian cancer will be diagnosed and 12,810 women will die of ovarian cancer in the United States by the end of 2022.Such alarming figures have increased concerns among the population not only in the country but globally. Rising awareness regarding the threat of ovarian cancer and its caused high mortality rates also substantiates the growth of the global ovarian cancer diagnostics market in the future five years. Market Segmentation The global ovarian cancer diagnostics market segmentation is based on diagnosis type, cancer type, end user, regional distribution, and competitive landscape.Based on diagnosis type, the market is further segmented into diagnostic imaging, blood test, biopsy, and others. Diagnostic imaging includes transvaginal ultrasound, CT scan, MRI scan, pet scan, and others.Blood tests include CA-125, HER2, BRCA, KRAS mutation, and others. The biopsy includes image-guided biopsy, fine needle aspiration biopsy, and others.By cancer type, the market is fragmented into epithelial tumors, germ cell tumors, stromal cell tumors, and others. Based on end users, the market is bifurcated into hospitals & specialty clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region. Company Profile Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., Quest Diagnostics, Inc., Siemens Healthineers AG, Thermo Fischer Scientific, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), MiRXES Pte Ltd, GinaLife, Luminex Corporation, Myriad Genetics Inc., are enlisted in a partial list of major market players of the global ovarian cancer diagnostics market. Report Scope: In this report, global ovarian cancer diagnostics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: • Ovarian Cancer Diagnostics Market, By Diagnosis Type: o Diagnostic Imaging
Mirxes Frequently Asked Questions (FAQ)
When was Mirxes founded?
Mirxes was founded in 2016.
What is Mirxes's latest funding round?
Mirxes's latest funding round is Series C.
How much did Mirxes raise?
Mirxes raised a total of $130.1M.
Who are the investors of Mirxes?
Investors of Mirxes include Rock Springs Capital, HYWOOD, CDG Capital, CCB International, EDBI and 8 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.